Atherosclerotic Plaque Imaging Project (CPIP)

Atherosclerotic Plaque Imaging Project (Identification of Vulnerable Atherosclerotic Plaques With Imaging and Biological Markers)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05821894

Acronym

APIP

Enrollment

3500

Registered

2023-04-20

Start date

2005-10-26

Completion date

2030-12-01

Last updated

2026-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerosis, Atherosclerotic Plaque

Brief summary

The rupture or erosion of an atherosclerotic plaque with thrombosis or embolization often underlie heart attacks and strokes. The early identification of patients with atherosclerotic plaques prone to rupture or erosions, vulnerable plaques (VP), and their treatment before the occurrence of events is, therefore, one of the greatest cardiovascular challenges today. Possible approaches for early detection of VP include imaging techniques allowing visualization of plaque structure, circulating biomarkers and better understanding of the pathophysiologic mechanisms of the disease. In the carotid plaque imaging project the investigators study human atherosclerotic plaques (that are removed by endarterectomy) to disclose their underlying structure and mechanisms, finding possible novel therapeutic targets or markers for VP. The investigators also study plaque structure with imaging methods and try to develop new ways to detect VP using circulating or imaging markers.

Interventions

OTHERObservational study

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients older than 18 years old, male or female that are eligible for carotid endarterectomy due to atherosclerosis and that can provide informed consent.

Exclusion criteria

* Patients younger than 18 years old that cannot provide informed consent; pregnant.

Design outcomes

Primary

Measure	Time frame	Description
Number of participants suffering post-operative cardiovascular events (by 2025)	Follow up assessment year 2025 (recording of events occurring since 2023)	Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)
Number of participants suffering post-operative cardiovascular events (by 2027)	Follow up assessment year 2027 (recording of events occurring since 2025)	Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)
Number of participants suffering post-operative cardiovascular events (by 2029)	Follow up assessment year 2029 (recording of events occurring since 2027)	Post-operative myocardial infarction, stroke, transient ischaemic attack, amaurosis fugax, cardiovascular death (according to Swedish National Registers)

Countries

Sweden

Contacts

CONTACTIsabel Goncalves, MD, PhD

Isabel.Goncalves@med.lu.se+46 40 331000

PRINCIPAL_INVESTIGATORIsabel Goncalves, MD, PhD

Lund University

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 9, 2026